ArticleEClinicalMedicine2025

Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.

Roberto Buonaiuto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.